Stéphane Verdood
Chief Executive Officer chez Vesalius Biocapital Holdings SA
Profil
Stéphane Verdood founded Arthur Andersen in 1995, where he worked as Principal, Vesalius Biocapital Partners SARL in 2007, where he is working as Managing Partner from 2007, and Value For Growth NV in 2001, where he worked as Managing Partner.
Mr. Verdood also currently works at Vesalius Biocapital Holdings SA, as Chief Executive Officer, Vesalius Biocapital II Holdings SARL, as Chief Executive Officer, Apitope International NV, as Chairman, Vesalius Biocapital I Investments SA SICAR, as Chairman, Vesalius Biocapital II Investments SA Sicar, as Chairman, Trod Medical NV, as Director from 2013, Apitope Technology (Bristol) Ltd., as Director, Vesalius Biocapital I SA SICAR, as Director, Vesalius Biocapital II SA SICAR, as Director, Vesalius Biocapital II Arkiv NV, as Managing Director, Forendo Pharma Oy, as Director, Scenic Biotech BV, as Non-Executive Director, Vesalius Biocapital Iii Partners SARL, as Director, Vesalius Biocapital Iii SCA Sicar, as Director, Vesalius Biocapital Iii Investments SA Sicar, as Director, Vesalius Biocapital Iii Portugal SARL, as Director & Manager, Vesalius Biocapital III CMF UG, as Director, Vesalius Biocapital Arkiv NV, as Managing Partner, Vesalius Biocapital II Partners SARL, as Managing Partner, and SGV Management Services BVBA, as Manager.
Mr. Verdood also formerly worked at Génomic Vision SA, as Vice Chairman-Supervisory Board from 2020 to 2022, Calliditas Therapeutics Suisse SA, as Director, Major SAS, as Director-Supervisory Board from 2010 to 2014, Biotechnological Enzymatic Catalyse NV, as Director, Fast Forward Pharmaceuticals BV, as Director, Genkyotex Innovation SAS, as Director, Mara Venture Partners, as General Partner from 2001 to 2006, and Vesale Partners SAS, as Member-Supervisory Board.
Mr. Verdood received his graduate degree and Masters Business Admin degree from Katholieke Universiteit Leuven.
Postes actifs de Stéphane Verdood
Sociétés | Poste | Début |
---|---|---|
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Director/Board Member | 01/06/2010 |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Founder | 15/07/2011 |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Chairman | - |
Trod Medical NV
Trod Medical NV Medical SpecialtiesHealth Technology Trod Medical NV develops and commercializes tools for use in the focal ablation of soft tissues. The company was founded by Andre Scattolin Faure on June 29, 2006 and is headquartered in Leuven, Belgium. | Director/Board Member | 30/10/2013 |
SGV Management Services BV | Corporate Officer/Principal | - |
Vesalius Biocapital Holdings SA | Chief Executive Officer | - |
Vesalius Biocapital I Investments SA SICAR
Vesalius Biocapital I Investments SA SICAR Investment ManagersFinance Part of Vesalius Biocapital Partners SARL, Vesalius Biocapital I Investments SA SICAR is a venture capital fund. The private company is based in Luxembourg, Luxembourg. | Chairman | - |
Vesalius Biocapital II Investments SA Sicar | Chairman | - |
Vesalius Biocapital II Partners SARL | Corporate Officer/Principal | - |
░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Anciens postes connus de Stéphane Verdood
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Stéphane Verdood
Katholieke Universiteit Leuven | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
GENOMIC VISION | Health Technology |
Entreprise privées | 30 |
---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Mara Venture Partners | Finance |
Arthur Andersen /Belgium/
Arthur Andersen /Belgium/ Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Arthur Andersen /Belgium/ is a Belgian company that provides accounting services. The private company is located in Belgium. The company was founded by Stéphane Verdood. Arthur Andersen /Belgium was acquired by Deloitte & Touche LLP from Arthur Andersen LLP on April 18, 2002. | Commercial Services |
Major SAS
Major SAS Apparel/Footwear RetailRetail Trade Major SAS is engaged in the manufactures and retails clothes for children. It's products include shirts, pants, shoes, T-shirts, pyjamas, frocks, overalls, pullovers, coats, and bathing slips. The company was founded by Paul Zemmour in 1987 and is headquartered in Montreuil, France. | Retail Trade |
Trod Medical NV
Trod Medical NV Medical SpecialtiesHealth Technology Trod Medical NV develops and commercializes tools for use in the focal ablation of soft tissues. The company was founded by Andre Scattolin Faure on June 29, 2006 and is headquartered in Leuven, Belgium. | Health Technology |
Biotechnological Enzymatic Catalyse NV
Biotechnological Enzymatic Catalyse NV Food: Major DiversifiedConsumer Non-Durables Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium. | Consumer Non-Durables |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Finance |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |
Vesalius Biocapital Arkiv NV
Vesalius Biocapital Arkiv NV Investment ManagersFinance Vesalius Biocapital Arkiv NV focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. Vesalius Biocapital Arkiv is part of the ARKImedes project which, is organized and/or managed by Participatiemaatschapij Vlaanderen NV. | Finance |
Vesalius Biocapital I Investments SA SICAR
Vesalius Biocapital I Investments SA SICAR Investment ManagersFinance Part of Vesalius Biocapital Partners SARL, Vesalius Biocapital I Investments SA SICAR is a venture capital fund. The private company is based in Luxembourg, Luxembourg. | Finance |
Vesalius Biocapital I SA SICAR
Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
Vesalius Biocapital II Investments SA Sicar | |
Vesalius Biocapital II SA SICAR
Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
Vesalius Biocapital II Partners SARL | |
Vesalius Biocapital II Arkiv NV
Vesalius Biocapital II Arkiv NV Investment ManagersFinance Vesalius Biocapital II Arkiv NV focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. Vesalius Biocapital Arkiv is part of the ARKImedes project, which is organized and/or managed by Participatiemaatschapij Vlaanderen NV. | Finance |
Value For Growth NV
Value For Growth NV Miscellaneous Commercial ServicesCommercial Services Value For Growth NV provides independent consulting and coaching services. The private company is based in Tervuren, Belgium. The Belgian company was founded by Gaston Mattyssens, Stéphane Verdood. | Commercial Services |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
Vesale Partners SAS | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
Vesalius Biocapital Holdings SA | |
Vesalius Biocapital II Holdings SARL | |
SGV Management Services BV | |
Genkyotex Innovation SAS
Genkyotex Innovation SAS BiotechnologyHealth Technology Part of Calliditas Therapeutics AB, Genkyotex Innovation SAS engages in research and development of biotechnology. The private company is based in Saint Julien-en-Genevois, France. | Health Technology |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Vesalius Biocapital Iii Partners SARL | |
Vesalius Biocapital Iii SCA Sicar | |
Vesalius Biocapital Iii Investments SA Sicar | |
Vesalius Biocapital Iii Portugal SARL | |
Vesalius Biocapital III CMF UG |